Novel approaches for treatment of endometrial carcinoma

被引：7

作者：

Garg, Vikas ^{[1
]}

Jayaraj, Aarthi S. ^{[1
]}

Kumar, Lalit ^{[1
,2
]}

机构：

[1] All India Inst Med Sci, Dept Med Oncol & Gynaecol, New Delhi, India

[2] All India Inst Med Sci, Dept Med Oncol, Room 234,IRCH Bldg,Second Floor, New Delhi 110029, India

来源：

CURRENT PROBLEMS IN CANCER | 2022年 / 46卷 / 05期

关键词：

Immunotherapy; Immune check points inhibitors; PD L-1 expression; Predictive biomarker; Novel therapies; pembrolizumab; mismatch repair; MSI; TKI; PHASE-II TRIAL; EXTERNAL-BEAM RADIOTHERAPY; PELVIC RADIATION-THERAPY; UTERINE SEROUS CARCINOMA; FIGO STAGE-I; OPEN-LABEL; VAGINAL BRACHYTHERAPY; HIGH-INTERMEDIATE; PD-L1; EXPRESSION; CANCER;

D O I：

10.1016/j.currproblcancer.2022.100895

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endometrial cancer (EC) is common malignancy in women and its incidence is slowly on the rise. Accu-rate surgical staging, with aggressive cytoreduction when indicated, remains the most critical step in the treatment. Careful pathological evaluation and/or molecular risk stratification guides for proper systemic adjuvant radiotherapy +/- chemotherapy. Recurrent and metastatic EC has dismal prognosis and palliative therapies (chemotherapy, hormonal therapy or radiation) forms the backbone of treatment. There is an un-met need of newer therapies to improve survival in such cases. A number of tyrosine kinase inhibitors are currently under evaluation. Recent data on therapeutic targeting of HER2 positive serous EC is excit-ing. Data on check point inhibitors particularly based on biomarker select population has raised hope for potentially effective treatment for women with high risk endometrial cancer .(c) 2022 Elsevier Inc. All rights reserved.

引用

页数：19

共 142 条

[1] Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies [J].

Aggarwal, R. ;

Umetsu, S. ;

Dhawan, M. ;

Grabowsky, J. ;

Carnevale, J. ;

Howell, M. ;

Wilch, L. ;

Chapman, J. ;

Alvarez, E. ;

Calabrese, S. ;

Smith, S. ;

Shah, N. ;

Dean, E. ;

Munster, P. ;

Collisson, E. .

ANNALS OF ONCOLOGY, 2021, 32 :S583-S583

[2] Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis [J].

Albright, Benjamin B. ;

Monuszko, Karen A. ;

Kaplan, Samantha J. ;

Davidson, Brittany A. ;

Moss, Haley A. ;

Huang, Allan B. ;

Melamed, Alexander ;

Wright, Jason D. ;

Havrilesky, Laura J. ;

Previs, Rebecca A. .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (03) :237-+

[3] Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study [J].

Alvarez, Edwin A. ;

Brady, William E. ;

Walker, Joan L. ;

Rotmensch, Jacob ;

Zhou, Xun C. ;

Kendrick, James E. ;

Yamada, S. Diane ;

Schilder, Jeanne M. ;

Cohn, David E. ;

Harrison, Charles R. ;

Moore, Kathleen N. ;

Aghajanian, Carol .

GYNECOLOGIC ONCOLOGY, 2013, 129 (01) :22-27

[4] Tim-3, a negative regulator of anti-tumor immunity [J].

Anderson, Ana Carrizosa .

CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) :213-216

[5]

[Anonymous], CORPUS UTERI GLOBAL

[6]

[Anonymous], PUBMED ENTRY

[7]

[Anonymous], 2019, CONS DOC MAN UT CANC

[8] Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). [J].

Antill, Yoland Catherine ;

Kok, Peey Sei ;

Robledo, Kristy ;

Barnes, Elizabeth ;

Friedlander, Michael ;

Baron-Hay, Sally E. ;

Shannon, Catherine M. ;

Coward, Jermaine ;

Beale, Philip James ;

Goss, Geraldine ;

Meniawy, Tarek ;

Yip, Sonia ;

Smith, Deborah ;

Spurdle, Amanda B. ;

Parry, Michelle ;

Andrews, John ;

Kelly, Marzena ;

Stockler, Martin R. ;

Mileshkin, Linda R. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[9] Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study [J].

Azad, Nilofer S. ;

Gray, Robert J. ;

Overman, Michael J. ;

Schoenfeld, Jonathan D. ;

Mitchell, Edith P. ;

Zwiebel, James A. ;

Sharon, Elad ;

Streicher, Howard ;

Li, Shuli ;

McShane, Lisa M. ;

Rubinstein, Larry ;

Patton, David R. ;

Williams, P. Mickey ;

Coffey, Brent ;

Hamilton, Stanley R. ;

Bahary, Nathan ;

Suga, J. Marie ;

Hatoum, Hassan ;

Abrams, Jeffrey S. ;

Conley, Barbara A. ;

Arteaga, Carlos L. ;

Harris, Lyndsay ;

O'Dwyer, Peter J. ;

Chen, Alice P. ;

Flaherty, Keith T. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) :214-+

[10] ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI) [J].

Banerjee, Susana ;

Stewart, James ;

Porta, Nuria ;

Toms, Christy ;

Leary, Alexandra ;

Lheureux, Stephanie ;

Khalique, Saira ;

Tai, Jeremy ;

Attygalle, Ayoma ;

Vroobel, Katherine ;

Lord, Christopher J. ;

Natrajan, Rachael ;

Bliss, Judith .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (11) :1471-1475

← 1 2 3 4 5 6 7 8 9 10 →